A personalized medicine product to predict toxicity to 5-FU-based chemotherapy
TheraGuide 5-FU assesses a persons risk of developing a severe toxic reaction to 5-FU-based chemotherapy. It detects variations in 2 genes, dihydropyrimidine dehydrogenase (DPYD) and thymidylate synthetase (TYMS), that are responsible for a significant portion of serious adverse reactions to 5-FU-based therapy.
Please visit the myriadtests.com website to learn more about how to identify patients at risk for developing 5-FU related toxicity.
Additional Resources
TheraGuide Website for Consumers
TheraGuide Website for Healthcare Professionals
Understanding a patient's risk profile allows the physician to administer 5-FU therapy more effectively.

